These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31404150)

  • 1. Corrigendum: Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength.
    Ebrahimi-Fakhari D; Dillmann U; Flotats-Bastardas M; Poryo M; Abdul-Khaliq H; Shamdeen MG; Mischo B; Zemlin M; Meyer S
    Front Pediatr; 2019; 7():284. PubMed ID: 31404150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-Label Use of Ataluren in Four Non-ambulatory Patients With Nonsense Mutation Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength.
    Ebrahimi-Fakhari D; Dillmann U; Flotats-Bastardas M; Poryo M; Abdul-Khaliq H; Shamdeen MG; Mischo B; Zemlin M; Meyer S
    Front Pediatr; 2018; 6():316. PubMed ID: 30406066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuitiy of care with ataluren in Duchenne Muscular Dystrophy patients with nonsense mutations after loss of ambulation. Personal experience.
    Spagnoli C; Adorisio R; Bello L; D'Amico A; D'Angelo MG; Pane M; Penzo M; Riguzzi P; Sansone V; Vianello A; Fusco C
    Acta Myol; 2023; 42(4):118-122. PubMed ID: 38406379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of ataluren in the treatment of ambulatory and non-ambulatory children with nonsense mutation duchenne muscular dystrophy - a consensus derived using a modified Delphi methodology in Eastern Europe, Greece, Israel and Sweden.
    Golli T; Juříková L; Sejersen T; Dixon C
    BMC Neurol; 2024 Feb; 24(1):73. PubMed ID: 38383326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients.
    McDonald CM; Muntoni F; Penematsa V; Jiang J; Kristensen A; Bibbiani F; Goodwin E; Gordish-Dressman H; Morgenroth L; Werner C; Li J; Able R; Trifillis P; Tulinius M;
    J Comp Eff Res; 2022 Feb; 11(3):139-155. PubMed ID: 34791888
    [No Abstract]   [Full Text] [Related]  

  • 6. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.
    Campbell C; Barohn RJ; Bertini E; Chabrol B; Comi GP; Darras BT; Finkel RS; Flanigan KM; Goemans N; Iannaccone ST; Jones KJ; Kirschner J; Mah JK; Mathews KD; McDonald CM; Mercuri E; Nevo Y; Péréon Y; Renfroe JB; Ryan MM; Sampson JB; Schara U; Sejersen T; Selby K; Tulinius M; Vílchez JJ; Voit T; Wei LJ; Wong BL; Elfring G; Souza M; McIntosh J; Trifillis P; Peltz SW; Muntoni F; ; ;
    J Comp Eff Res; 2020 Oct; 9(14):973-984. PubMed ID: 32851872
    [No Abstract]   [Full Text] [Related]  

  • 7. A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy.
    Landfeldt E; Sejersen T; Tulinius M
    Acta Paediatr; 2019 Feb; 108(2):224-230. PubMed ID: 30188594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of face validity of a disease model of nonsense mutation Duchenne muscular dystrophy: a multi-national Delphi panel study.
    Landfeldt E; Zhang R; Childs AM; Johannsen J; O'Rourke D; Sejersen T; Strautmanis J; Schara-Schmidt U; Tulinius M; Walter MC; Willis T; Buesch K
    J Med Econ; 2022; 25(1):808-816. PubMed ID: 35642753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic approach with Ataluren in Duchenne symptomatic carriers with nonsense mutations in dystrophin gene. Results of a 9-month follow-up in a case report.
    D'Ambrosio P; Orsini C; Nigro V; Politano L
    Acta Myol; 2018 Dec; 37(4):272-274. PubMed ID: 30944907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry.
    Muntoni F; Desguerre I; Guglieri M; Osorio AN; Kirschner J; Tulinius M; Buccella F; Elfring G; Werner C; Schilling T; Trifillis P; Zhang O; Delage A; Santos CL; Mercuri E
    J Comp Eff Res; 2019 Oct; 8(14):1187-1200. PubMed ID: 31414621
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy.
    Landfeldt E; Lindberg C; Sejersen T
    Muscle Nerve; 2020 Mar; 61(3):363-368. PubMed ID: 31875971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year follow up of three Italian patients with Duchenne muscular dystrophy treated with ataluren: is earlier better?
    Ruggiero L; Iodice R; Esposito M; Dubbioso R; Tozza S; Vitale F; Santoro L; Manganelli F
    Ther Adv Neurol Disord; 2018; 11():1756286418809588. PubMed ID: 30542376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment.
    Li M; Andersson-Lendahl M; Sejersen T; Arner A
    FASEB J; 2014 Apr; 28(4):1593-9. PubMed ID: 24371125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Correlation of Skeletal and Cardiac Muscle Dysfunction in Duchenne Muscular Dystrophy.
    Posner AD; Soslow JH; Burnette WB; Bian A; Shintani A; Sawyer DB; Markham LW
    J Neuromuscul Dis; 2016; 3(1):91-99. PubMed ID: 27182492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.
    Mah JK
    Methods Mol Biol; 2018; 1687():3-17. PubMed ID: 29067652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy.
    Namgoong JH; Bertoni C
    Degener Neurol Neuromuscul Dis; 2016; 6():37-48. PubMed ID: 30050367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
    Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
    Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model.
    Williams K; Davidson I; Rance M; Boehnke A; Buesch K; Acaster S
    J Patient Rep Outcomes; 2021 Aug; 5(1):75. PubMed ID: 34420127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy.
    Bello L; Pegoraro E
    Acta Myol; 2016 Dec; 35(3):122-127. PubMed ID: 28484312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.